COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? No

Brett Ley¹

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Kaiser Permanente San Francisco, and the Department of Medicine, University of California San Francisco. Electronic address: brett.ley@ucsf.edu.

Editorial

Brett Ley. Chest. 2019 Aug.

. 2019 Aug;156(2):205-208.

doi: 10.1016/j.chest.2019.03.027.

Brett Ley¹

¹ Department of Pulmonary and Critical Care Medicine, Kaiser Permanente San Francisco, and the Department of Medicine, University of California San Francisco. Electronic address: brett.ley@ucsf.edu.

No abstract available

Comment in

Rebuttal From Dr Prasse.
Prasse A. Prasse A. Chest. 2019 Aug;156(2):208-209. doi: 10.1016/j.chest.2019.03.029. Chest. 2019. PMID: 31395257 No abstract available.
A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease.
Raghu G, Colby TV, Myers JL, Steele MP, Benzaquen S, Calero K, Case AH, Criner GJ, Nathan SD, Rai NS, Hagmeyer L, Davis JR, Bhorade SM, Kennedy GC, Gauher UA, Martinez FJ. Raghu G, et al. Chest. 2020 May;157(5):1391-1392. doi: 10.1016/j.chest.2019.10.061. Chest. 2020. PMID: 32386639 No abstract available.